Expression of the multidrug resistance P glycoprotein (Pgp) and multidrug resistance associated protein (MRP1) in Down syndrome brains
Transport by ATP-dependent efflux pumps such as P glycoprotein (Pgp) and multidrug resistance associated protein (MRP), encoded by multidrug resistant (MDR) associated genes, is an increasingly recognized mechanism by which cells maintain substrate homeostasis and evade drug therapy. Pgp and MRP are members of the so-called ATP binding cassette (ABC) transporters superfamily, which are associated with many biological processes in both prokaryotes and eukaryotes, as well as clinical problems. The observation of upregulated sequences that are homologous to the Mycobacterium smegmatis phage resistance (mpr) gene and putative ABC transporters subunits in fetal Down syndrome (DS) using the gene hunting technique, subtractive hybridization formed the Rationale for this study. The expression of Pgp and MRP1 is therefore investigated in different brain regions of controls and adult DS patients with western blot technique. No apparent changes were observed between controls and DS in levels of Pgp in all brain regions examined. By contrast, MRP1 detection using the rat monoclonal antibody (MRPrl) produced a significant elevation in DS temporal cortex (P < 0.01) and parietal cortex (P < 0.05). Although MRP1 detected with the mouse monoclonal antibody (MRPm6) tended to increase in most of the regions of DS brain, it failed to reach significance level. Age or postmortem interval did not correlate with protein levels in both controls as well as DS. Taken together, the current data provide evidence for the presence of MDR related pumps in different regions of the human brain. In addition, overexpression of MRP1 in DS brain may have some relevance to the disorder either by deranging substrate homeostasis or limiting drug access.
KeywordsDown Syndrome Multidrug Resistance Multi Drug Resistance Associate Protein Multidrug Resistance Protein Multidrug Resistance Related Protein
Unable to display preview. Download preview PDF.
- Epstein CJ (2001) Down syndrome (Trisomy 21). In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease. McGraw Hill, New York, pp 1223–1256Google Scholar
- Grandjean F, Bremaud L, Verdier M, Robert J, Ratinaud M-H (2001) Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicinresistant human K562 cell lines. Anti-Cancer Drugs 12: 247–258PubMedCrossRefGoogle Scholar
- Iannello RC, Crack PJ, de Haan JW, Kola I (1999) Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm 57: 257–267Google Scholar
- Rao V, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica- Worms D (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance associated protein contribute to the blood cerebrospinal fluid drug permeability barrier. Proc Natl Acad Sci USA 96: 3900–3905PubMedCrossRefGoogle Scholar
- Scheper RJ, Bulte JW, Brakkee JGP, Quak JJ, van Der Schoot E, Balm AJM, Meijer CJLM, Broxterman HJ, Kuiper CM, Lankelma J, Pinedo HM (1988) Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycosylation associated with multidrug resistance. Int J Cancer 42: 389–394PubMedCrossRefGoogle Scholar
- Wang F, Dong Z, Luo J (1998) The clinical significance of multidrug resistance associated (MRP) gene exression in acute leukemia. Zhonghua Xve Ye Xue Za Zhi 19: 63–66Google Scholar
- Zaman GJR, Versantvoort CHM, Smith JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EGE, Baas F, Borst P (1993) Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multi drug resistant lung cancer cell lines. Cancer Res 53: 1747–1750PubMedGoogle Scholar